Physician Assistant Program year 2025 Reported 2022–2025 Source: CMS Open Payments, 2026 publication

Autumn Venturelli

Physician Assistant Statesboro, GA Physician Assistant

NPI 1376208033 CMS profile 11386196

19 Coach Lee Hill Blvd, Statesboro, GA 30458

Open in the dashboard

General payments

$5,209

268 records reported · program years 2022–2025

Research payments

$0

Paid to them · None reported · program years 2022–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Autumn Venturelli of Statesboro, GA is reported in the CMS Open Payments database as having received $5,209 across 268 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 92nd percentile of Physician Assistant profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

4 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $2,167 117
2024 General $1,580 83
2023 General $1,059 47
2022 General $403 21

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Autumn Venturelli
  • Physician Assistant median
  • Middle half of Physician Assistant
  • National median

In program year 2025, general payments to Autumn Venturelli were reported at $2,167. Among 68,903 Physician Assistant profiles paid that year, the median was $184 and the middle half received between $57 and $620.

Show as a table
Year Autumn Venturelli Physician Assistant median Middle half National median
2019 $0 $34 $17–$122 $163
2020 $0 $33 $16–$78 $114
2021 $0 $132 $37–$438 $132
2022 $403 $155 $48–$522 $149
2023 $1,059 $167 $52–$557 $160
2024 $1,580 $178 $55–$600 $164
2025 $2,167 $184 $57–$620 $169

Breakdown

Who paid General payments · program years 2022–2025
  1. AbbVie, Inc. $1,952 103 payments
  2. Janssen Biotech, Inc. $659 41 payments
  3. QOL Medical, LLC $443 14 payments
  4. Salix Pharmaceuticals, a division of Bausch Health US, LLC $248 13 payments
  5. Takeda Pharmaceuticals U.S.A., Inc. $216 12 payments
  6. Ardelyx, Inc. $199 13 payments
  7. Phathom Pharmaceuticals, Inc. $149 10 payments
  8. Axsome Therapeutics, Inc. $139 5 payments
  9. Regeneron Healthcare Solutions, Inc. $136 5 payments
  10. Neurocrine Biosciences, Inc. $106 4 payments
  11. Other $962 48 payments

Every payment, record by record

What the payments were for General payments · program years 2022–2025
  1. Food and Beverage $5,148 267 payments
  2. Education $61 1 payment
Products named General payments · program years 2022–2025
  1. RINVOQ $790 40 payments
  2. LINZESS $557 34 payments
  3. SKYRIZI Immunology $505 24 payments
  4. CREON $452 29 payments
  5. SKYRIZI Immunology $433 19 payments
  6. TREMFYA $394 28 payments
  7. VRAYLAR $334 14 payments
  8. Sucraid $319 10 payments
  9. STELARA $265 13 payments
  10. IBSRELA $199 13 payments
  11. Other $2,260 117 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 16 drugs

Part D claims

913

Median for Physician Assistant: 241

Drug cost

$93,589

Median for Physician Assistant: $4,110

Branded share of claims

38.6%

Median for Physician Assistant: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Linzess Linaclotide Brand 61 $56,837
Motegrity Prucalopride Succinate Brand 15 $12,215
Sod Sulf-Potass Sulf-Mag Sulf Sodium, Potassium,mag Sulfates Brand 142 $9,659
Dexlansoprazole Dr Dexlansoprazole Brand 12 $2,933
Pantoprazole Sodium Generic 193 $2,830
Dicyclomine Hcl Generic 64 $1,702
Omeprazole Generic 122 $1,610
Ondansetron Odt Ondansetron Brand 58 $1,476
Colestipol Hcl Generic 13 $1,046
Famotidine Generic 116 $982

The 10 drugs with the highest cost, of 16 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 114,276 Part D prescribers listed as Physician Assistant; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 7 billing codes

Paid by Medicare

$44,608

Medicare's payments for the services billed

Medicare patients

402

Average age 73

Services billed

565

226 women, 176 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 52%
Diabetes 29%
Ischemic heart disease 26%
Chronic kidney disease 23%
Depression 20%
Cancer 19%
Atrial fibrillation 17%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 21 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
SKYRIZI
  • AbbVie, Inc. $265
$265 — —
RINVOQ
  • AbbVie, Inc. $196
$196 — —
STELARA
  • Janssen Biotech, Inc. $152
$152 — —
LINZESS
  • AbbVie, Inc. $105
  • Ironwood Pharmaceuticals, Inc $21
$127 61 —
Sucraid
  • QOL Medical, LLC $124
$124 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 21 in the dashboard with a free account

Records

268 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Physician Assistant in Georgia

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record